Please provide your email address to receive an email when new articles are posted on . Despite a decline in herpes simplex virus type 2 infections over the course of decades, researchers calculated ...
Detailed price information for Theralase Technologies Inc. (TLT-X) from The Globe and Mail including charting and trades.
The rise of sexually transmitted infections (STIs) continues to pose threats. The prevalence of one uncurable STI in particular – genital herpes simplex virus (HSV) type 1 and 2 – is at a global high, ...
Background. Herpes simplex virus type 2 (HSV-2) reactivations are associated with increased HIV load, but whether HSV-2 coinfection accelerates HIV disease is unclear. We compared rates of CD4 count ...
HealthDay News — A once-promising investigational vaccine against herpes viruses showed only 20% efficacy against herpes genital disease in a large clinical trial designed to mimic the general ...
Herpes simplex virus is a master of bad timing—reappearing briefly, often unnoticed, and just long enough to keep the immune system on its toes. In its genital form, herpes simplex virus type 2 (HSV-2 ...
Assembly Biosciences (NASDAQ:ASMB) reported promising results from an early stage study of its experimental candidate, ABI-5366, a new treatment aimed against herpes simplex virus. This study involved ...
WOBURN, Mass. and OXFORD, England, July 8, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced ...
WOBURN, Mass. and OXFORD, England, Dec. 14, 2021 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today ...
Molly Rosenberg, Audrey Pettifor, Sheri A. Lippman, Harsha Thirumurthy, Michael Emch, William C. Miller, Amanda Selin, Francesc Xavier Gómez-Olivé, James P. Hughes ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results